ArticleBMC cancer2018

Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.

Peter J Klauck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.